Ratings IRRAS AB

Equities

IRRAS

SE0008321202

Market Closed - Nasdaq Stockholm Other stock markets 07:59:43 2023-11-03 am EDT			5-day change	1st Jan Change
0.1604 ^SEK	-1.11%		-.--%	-.--%

2023	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
2023	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
IRRAS AB	-.--%	16.63M		C
STRYKER CORPORATION	+12.72%	129B		A-
SMITH & NEPHEW PLC	-9.23%	10.77B		A-
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+2.17%	9.05B		C
INSPIRE MEDICAL SYSTEMS, INC.	+19.60%	7.38B		C
GLAUKOS CORPORATION	+21.94%	4.88B		B+
AXONICS, INC.	+7.27%	3.41B		C-
ENOVIS CORPORATION	-0.55%	3.07B		B-
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-5.07%	2.24B	-	-
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-4.22%	2.12B		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders